Black Diamond Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference

Black Diamond Therapeutics plans a webcast fireside chat and investor meetings at the H.C. Wainwright Global Investment Conference.

Rhea-AI Summary

Black Diamond Therapeutics (BDTX)/b) will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, NY.The session featuring Chief Scientific Officer Elizabeth Buck, Ph.D., is scheduled for 10:00–10:30 a.m. ET. A live webcast and 90-day replay will be available under “Events and Presentations” in the Investors section of the company’s website. The company will also host one-on-one investor meetings that day.

Market Context

BDTX declined 35.77% after the May 22 conference-participation announcement. That precedent shows va...

Analysis

BDTX declined 35.77% after the May 22 conference-participation announcement. That precedent shows varied responses to event notices; the active S-3 permits offerings up to $500,000,000, making event follow-through the key item to watch.

Key Figures

Conference edition: 28th Conference date: September 15, 2026 Presentation time: 10:00-10:30am ET +1 more

4 metrics

Conference edition 28th H.C. Wainwright Global Investment Conference

Conference date September 15, 2026 Fireside chat and investor meetings

Presentation time 10:00-10:30am ET September 15, 2026 presentation

Webcast replay period 90 days Following the event

Historical Context

5 past events · Latest: Aug 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Q2 earnings report	Positive	+7.3%	Reported clinical progress and cash runway extending into the second half of 2028
May 22	Healthcare conference participation	Neutral	-35.8%	Announced CEO fireside chat at the Jefferies Global Healthcare Conference
May 21	Phase 2 clinical data	Positive	-35.8%	Reported positive silevertinib results in frontline EGFR-mutant NSCLC
May 19	Clinical data webcast	Neutral	+16.3%	Scheduled webcast highlighting updated Phase 2 silevertinib results
May 07	Q1 earnings report	Neutral	-3.5%	Reported first-quarter results and provided a corporate development update

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent reactions diverged across event types: positive Phase 2 data preceded a 35.77% decline, while Q2 results preceded a 7.26% gain.

Key Terms

oncogenic mutations, brain-penetrant, egfr inhibitor

3 terms

oncogenic mutations medical

"therapies that target families of oncogenic mutations in patients with cancer"

Oncogenic mutations are changes in a cell's DNA that push the cell to grow and divide uncontrollably, transforming a normal cell toward cancer. They matter to investors because pinpointing which mutations cause disease guides the creation of targeted drugs, diagnostics and tests — similar to finding the exact broken part in a machine so a company can build a precise repair with clear market and regulatory value.

brain-penetrant medical

"a potential best-in-class brain-penetrant epidermal growth factor receptor"

A brain-penetrant drug or molecule can cross the brain’s natural security gate (the blood–brain barrier) to reach and act on cells inside the brain. For investors, that matters because treatments that reach the brain can address disorders like Alzheimer’s, depression, or brain cancer—opening large markets—but they also carry higher technical risk, stricter safety testing and unique regulatory challenges compared with drugs that act elsewhere in the body.

egfr inhibitor medical

"epidermal growth factor receptor (EGFR) inhibitor"

An epidermal growth factor receptor (EGFR) inhibitor is a medicine that blocks a specific protein on some cancer cells that acts like a ‘on’ switch for growth; by turning that switch off, the drug can slow or stop tumor growth. Investors care because these drugs are often tied to clear clinical tests, targeted patient groups, patent-protected sales and regulatory decisions, so trial results, safety issues or approvals can sharply change a company’s value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CAMBRIDGE, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer, including silevertinib, a potential best-in-class brain-penetrant epidermal growth factor receptor (EGFR) inhibitor, today announced that its Chief Scientific Officer, Elizabeth Buck, Ph.D., will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026, in New York, NY. In addition, the Company will host one-on-one meetings with investors on the same day.

Presentation details are as follows:

• 10:00-10:30am ET on Tuesday, September 15
  

The Webcast will be available at the start of the presentation under “Events and Presentations” on the Investors section of the Company’s website, www.blackdiamondtherapeutics.com. A replay of the webcast will also be available and archived for 90 days following the event.

About Silevertinib

Silevertinib is an investigational oral, covalent, brain-penetrant fourth-generation tyrosine kinase inhibitor (TKI) that has demonstrated best-in-class CNS activity, selectively targeting classical and more than 50 non-classical EGFR mutations in NSCLC. It is also designed to potently inhibit key EGFR alterations seen in GBM, including EGFRvIII, while avoiding the paradoxical EGFR activation reported with reversible TKIs. To date, over 200 patients with EGFRm NSCLC or EGFR-altered GBM have been treated with silevertinib.

In addition to the ongoing Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, the Company also initiated a randomized Phase 2 trial of silevertinib in patients with newly diagnosed EGFRvIII-positive GBM (NCT07326566) in May 2026.

About Black Diamond Therapeutics

Black Diamond Therapeutics is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The Company’s MasterKey therapies are designed to address a broad spectrum of genetically defined tumors, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system disease. The Company is advancing silevertinib, an investigational brain-penetrant fourth-generation EGFR MasterKey inhibitor targeting EGFR-mutant NSCLC and GBM. For more information, please visit www.blackdiamondtherapeutics.com.

Contacts

For Investors:
investors@bdtx.com

For Media:
media@bdtx.com 

FAQ

When will Black Diamond Therapeutics (BDTX) present at the H.C. Wainwright 28th Annual Global Investment Conference?

Black Diamond Therapeutics is scheduled for a fireside chat on Tuesday, September 15, 2026, from 10:00–10:30 a.m. ET during the H.C. Wainwright 28th Annual Global Investment Conference in New York, NY.

How can investors access the Black Diamond Therapeutics (BDTX) webcast from the H.C. Wainwright conference?

The live webcast will be available at the start of the presentation under “Events and Presentations” in the Investors section of Black Diamond Therapeutics’ website. A replay will be archived and accessible for 90 days following the event.

Will Black Diamond Therapeutics (BDTX) hold investor meetings at the H.C. Wainwright 2026 conference?

Yes. On September 15, 2026, Black Diamond Therapeutics will host one-on-one meetings with investors in addition to its scheduled fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference.